Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
BCG vaccination and the risk of COVID-19: A possible correlation

Sara M. Ahmed a, Mohamed A. Nasr a, Shimaa E. Elshenawy a, Alaa E. Hussein a, Ahmed H. El-Betar b, Rania Hassan Mohamed c, Nagwa El-Badri a,∗

a Center of Excellence for Stem Cells and Regenerative Medicine (CESC), Zewail City of Science and Technology, October Gardens, 12582, 6th of October City, Giza, Egypt
b Department of Urology, Ahmed Maher Teaching Hospital, Cairo, Egypt
c Department of Biochemistry, Faculty of Science, Ain Shams University, Egypt

ARTICLE INFO

Keywords:
BCG
COVID-19
SARS-CoV-2
Bacillus Calmette-Guérin
Monocytes
Macrophages
Gene expression

ABSTRACT

Bacillus Calmette-Guérin (BCG) vaccine is currently used to prevent tuberculosis infection. The vaccine was found to enhance resistance to certain types of infection including positive sense RNA viruses. The current COVID-19 pandemic is caused by positive sense RNA, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A higher mortality rate of COVID-19 patients was reported in countries where BCG vaccination is not routinely administered, when compared to the vaccinated ones. We hypothesized that BCG vaccine may control SARS-CoV-2 infection via modulating the monocyte immune response. We analyzed GSE104149 dataset to investigate whether human monocytes of BCG-vaccinated individuals acquire resistance to SARS-CoV-2 infection. Differentially expressed genes obtained from the dataset were used to determine enriched pathways, biological processes, and molecular functions for monocytes post BCG vaccination. Our data show that BCG vaccine promotes a more effective immune response of monocytes against SARS-CoV-2, but probably not sufficient to prevent the infection.

1. Introduction

Bacillus Calmette-Guerin (BCG) vaccine is used primarily to treat tuberculosis infection. There are several reports on the role of BCG vaccination in non-specific modulation of the immune responses against various types of infection (Moorlag et al., 2019; Arnoldussen et al., 2011). During tuberculosis outbreaks, a decrease in respiratory tract infections, such as influenza A and yellow fever viruses was observed in BCG vaccinated patients (Moorlag et al., 2019; Arnoldussen et al., 2011; Arts et al., 2018a). A randomized clinical trial showed a decrease in lower respiratory tract infection in patients older than 65 years post-BCG vaccination (Giamarellos-Bourboulis et al., 2020). Other studies reported that BCG vaccine ameliorated the severity of positive sense RNA viruses, such as mengovirus and yellow fever virus (Arts et al., 2018a). The mechanism underlying this effect was attributed to genetic or epigenetic modulation of the innate immune system in a process known as trained immunity (Arts et al., 2018a; Patella, 2020). Trained immunity is initiated through the response of innate immune cells to microbial antigen that causes epigenetic and metabolic changes, that upon re-infection, a more significant response to the antigen occurs (Netea et al., 2011; Sánchez-Ramon et al., 2018).

The current COVID-19 pandemic is caused by the positive sense RNA virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological studies reported decreased mortality rate of BCG vaccinated individuals who were infected with SARS-CoV-2 (Curtis et al., 2020; Ozdemir et al., 2020). It was thus proposed that BCG vaccine may be effective against SARS-CoV-2. The main mode of SARS-CoV-2 transmission is via droplets and direct contact (Shafaghi et al., 2020; Tung et al., 2021). Patients with COVID-19 present mainly with fever and dry cough that may be complicated with acute respiratory distress syndrome (ARDS), cardiac, gastrointestinal, renal or even central nervous system complications (Wang et al., 2020). Ongoing randomized controlled trials in many countries such as Netherlands and Australia (NCT04327206 and NCT04328441) are designed to determine the effect of BCG vaccine on SARS-CoV-2 infection rate. Other study compared the rate of death after COVID-19 in all countries according to their BCG vaccination (Gursel and Gursel, 2020).

* Corresponding author. Center of Excellence for Stem Cells and Regenerative Medicine (CESC), Zewail City of Science and Technology, Sheikh Zayed District, 12588, 6th of October City, Giza, Egypt.
E-mail address: nelbadri@zewailcity.edu.eg (N. El-Badri).

https://doi.org/10.1016/j.virol.2021.10.003
Received 24 May 2021; Received in revised form 1 October 2021; Accepted 17 October 2021
Available online 28 October 2021
0042-6822/© 2021 Published by Elsevier Inc. This article is made available under the Elsevier license (http://www.elsevier.com/open-access/userlicense/1.0/).
2. BCG immune response

Epidemiological studies have shown that BCG vaccination significantly decreased child mortality in Europe in the 1920's. Randomized controlled trials showed that there is a reduction in BCG-induced mortality in young infants by up to 50% (Aaby et al., 1984, 2011). These studies did not however distinguish between bacterial and viral infections, although it is well documented that viral pathogens are the major cause of respiratory tract infections in children (Stensballe et al., 2005). BCG vaccine boosted the innate immune response upon re-stimulation with different infectious pathogens, in a process known as “trained immunity” (Kleinijnenhuis et al., 2015). Despite the fact that the vaccine has been designed and used against Mycobacterium tuberculosis, studies have shown cross-prevention against other non-relevant pathogens, including viruses such as yellow fever (Arts et al., 2018b), hepatitis B, and influenza (H1N1) (Covian et al., 2019) (Zimmermann and Curtis, 2018). Recombinant BCG vaccine was also reported to help against respiratory viruses causing pneumonia and other airway complications (Soto et al., 2018). Vaccination with BCG vaccine has been reported to reduce susceptibility to acute upper and lower respiratory tract infections (Aaby et al., 1984, 2011; Stensballe et al., 2005; Zhu, 2020). The effectiveness of BCG was attributed to epigenetic modifications in stimulated monocytes leading to regulation and induction of cytokines, such as CXCL10, CXCL8, CCL3, CCL3L1 and IL1B.

3. Inflammatory response of monocytes against SARS-COV-2

Serious infection with SARS-CoV-2 causes a gush in pro-inflammatory cytokines, known as cytokine storm (Shin et al., 2009; Spencer et al., 1977; Zhang, 2020). These cytokines include IL-6, TNFα, and IL-10 (Rocha et al., 2013; Thacker and Zdzenicka, 2004). Viremia was also shown to be critical in the pathogenesis of severe COVID-19, where viral particles were present in the brain, kidney and heart of autopsy samples of 27 severely infected patients (Thacker and Zdzie nicka, 2003). Entry of viral particles occurs through the angiotensin-converting enzyme-2 (ACE2) receptors on the cell surface of these tissues may explain the severity of the disease (Freund et al., 2010; Campisi and Di Fagagna, 2007). Monocytes/macrophages were reported to play a central role in the fatality of COVID-19 as shown in several recent studies (Kuilman et al., 2008, 2010; Orjalo et al., 2009; Acosta et al., 2013). The immune cell profile of COVID-19 patients with mild, severe, and critical disease in cross sectional study showed a decrease in the total circulating monocytes. Specifically, there was an increase in the percentage of intermediate (CD14+CD16−) and non-classical (CD14−CD16+) monocytes in severe and critical cases (Zhou et al., 2020). Pulmonary tissue of transgenic mice with human ACE2 receptors showed greater influx with monocytes/macrophages following SARS-CoV-2 infection (Reaven, 1988). Bronchoalveolar lavage of 9 patients with COVID-19 showed an increase in the proportion of lung macrophages in severe cases relative to mild ones (Jun et al., 1999). These macrophages were not tissue-resident, but were monocyte-derived Fcn1+ cells that displayed an activation of inflammatory pathways (Jun et al., 1999). In another study of 14 hospitalized patients, an increase in hyperactivated pulmonary macrophage was reported in severe cases (Volpe et al., 2018). Another study reported a decrease in monocytes expression of HLA-DR in comparison to patients with milder COVID-19. The decrease in HLA-DR expression was usually observed immediately prior the progress of the case into severe ARDS (Choo et al., 2019).

Interestingly, older individuals were found to suffer a severe form of COVID-19 and higher mortality compared to younger adults (El-Badawy and El-Badry, 2016; El-Badawy et al., 2016; Panina et al., 2018; Elkehann et al., 2016; Smith and Reid, 2018). A study of 33 COVID-19 patients reported an increase in the peripheral blood CD14+CD16+ monocytes, which increased even further in patients with ARDS (Bhansali et al., 2009). CD14+ CD16+ monocytes are considered the intermediate monocytes that exist in a lower proportion, of around 5% in healthy individuals. Monocytes showed an increased secretion of pro-inflammatory cytokine; IL-6 in mild cases, and increased secretion in severe cases, indicating an important role in COVID-19 cytokine storm. IL-6 induces acute phase response through the stimulation of prostaglandin from brain endothelial cells (Brandl et al., 2011). CD14+CD16− monocytes isolated from blood of 28 patients with COVID-19 acquired macrophage markers suggesting monocytes differentiation (Lee et al., 2019). These cells contributed to the cytokine storm by secreting inflammatory cytokines such as IL-6, TNFα, and IL-10. Patients with severe COVID-19 showed increased proportion of these inflammatory cells (Seo et al., 2017). Because of this role of IL-6 in the cytokine storm, its blockage is now a therapeutic target for severe COVID-19 (Zhang et al., 2012). IL-6 also controls differentiation of monocytes to macrophage by shutting down the switch of monocytes to dendritic cells and transforming them into macrophages (Madonna et al., 2014). Monocytes also express ACE2, which is the main entry receptor for SARS-CoV-2 in most of human tissues (Zhang, 2020). ACE2 receptors are involved in the vascular homeostasis via controlling renin-angiotensin-aldosterone system (RAAS) and thus regulating hyper tension and vascular inflammation (Yao and Brownlee, 2010; Hao et al., 2013; Chang et al., 2015). Monocytes infection with SARS-COV-2 may impair vascular hemostasis. In this paper, we analyze published data to investigate whether human monocytes of BCG vaccinated individuals are modulated to be more effective against SARS-COV-2.

4. Methods

4.1. Data search

We used the dataset GSE104149 from the Gene Expression Omnibus (GEO) library (Arts et al., 2018b; Mourtis et al., 2020). This dataset shows the changes on monocytes epigenome and transcriptome levels after one month of BCG vaccine administration. The data were obtained from six experimental groups, and six controls.

4.2. Data analysis

GEO2R tool only analyzes microarray data and thus could not be used to assess differentially expressed (DE) genes in high throughput sequencing data. We thus used the GEO RNA-seq Experiments Interactive Navigator (GREEN) to perform data analysis for differentially expressed (DE) genes (Mahi et al., 2019).

5. Results

Our analysis generated gene expression profiles of about 26175 genes (including some gene duplicates), which were then filtered by elimination of statistically non-significant data (P-value < 0.05). The use of P-value instead of the adjusted P-value was based on the fact that the sample size was too small for using the latter. This was supported by obtaining the same adjusted value for all genes expression (value = 1), which was not sufficient for data filtering. Only 89 genes out of the 26,175 were found to be statistically significant and were used for downstream analysis, as shown in (Supplementary Table 1).

We then used Enrichr online enrichment analysis tool in search for the biological processes, and molecular functions enriched by these genes (Chen et al., 2015; Kuleshov et al., 2016). Kyoto Encyclopedia of genes and genomes database (KEGG) 2019 was used to obtain pathway enrichment, while gene ontology for biological processes and molecular functions were obtained from GO Biological Process 2018 and GO Molecular Function 2018 databases, respectively. The top statistically significant outputs, ranked by their adjusted p values (<0.05) were selected (Table 1).

Using OLSVis (an interactive ontology visualizer) and QuickGO, negative regulation of viral genome replication (GO:0045071) was
found to be a “child term” for regulation of viral genome replication (GO: 0045069), and negative regulation of viral life cycle (GO: 1903901) (Vercruysse et al., 2012; Binns et al., 2009). All of these 3 GO biological processes showed the same set of enriched genes similar the ones obtained from our selected GEO dataset, except for GO:0045071, which obtained an additional gene, CXCL8. We used Gene ontology and AmiGO 2 tools to obtain annotations of the previously mentioned common genes in the context of their GO biological process (Ashburner et al., 2000; The Gene Ontology Resourc, 2019; Carbon et al., 2008).

Moreover, using PANTHER (a GO enrichment analysis tool), we were able to identify the PANTHER family of these genes, in addition to the biological processes in which each gene is involved (Table 4). We compared the whole set of genes that were enriched for viral biological processes, obtained from GO Biological Processes 2018 and PANTHER overrepresentation test (using VennPainter tool) and found 7 genes to be commonly enriched, while 3 common biological processes to be enriched by these genes which makes these genes and biological processes in which each gene is involved (Table 4).

### Table 1

| Rank | Pathway                                      | Adj. P-value | Genes involved                        |
|------|----------------------------------------------|--------------|---------------------------------------|
| 1    | Toll-like receptor signaling pathway         | 0.025        | CXCL10, CXCL8, CCL3L1, IL1B, CCL3     |
| 2    | Cellular response to type I interferon       | 3.93E-08     | IFITM1, RSAD2, IFI27, ISG15, HLA-A, IFIT1, IFIT2, OASL |
| 3    | Regulation of viral genome replication       | 4.14E-07     | IFITM1, CXCL8, RSAD2, IFI2AK2, ISG15, HLA-A, IFIT3, IFIT2, OASL |
| 4    | Negative regulation of viral genome replication | 2.14E-06    | IFITM1, RSAD2, IFI2AK2, ISG15, IFIT1, APOBECA3A, OASL |
| 5    | Negative regulation of viral life cycle      | 7.20E-06     | IFITM1, RSAD2, IFI2AK2, ISG15, IFIT1, APOBECA3A, OASL |
| 6    | Cytokine-mediated signaling pathway          | 5.34E-05     | IFITM1, CXCL8, RSAD2, CCL3L1, ISG15, HLA-A, PPPB, IFIT1, IFIT3, OASL, IFIT2, CXCL10, IFI27, IL1B, CCL3 |
| 7    | Chemokine-mediated signaling pathway         | 0.002        | CXCL10, CXCL8, CCL3L1, CCL3, PPPB |
| 8    | Inflammatory response                        | 0.008        | CXCL10, CXCL8, CCL3L1, NLRP7, IL1B, CCL3, PPPB, SIGLEC1 |
| 9    | Cellular response to lipopolysaccharide      | 0.024        | CXCL10, CXCL8, NLRP7, IL1B, CCL3 |

### Table 2

| GO ID | Gene                               | PANTHER family                  | Biological Process                                      |
|-------|------------------------------------|---------------------------------|--------------------------------------------------------|
| GO:0045069 | IFIT1                            | Interferon-induced protein with tetratricopeptide repeat | Defense response to virus |
| GO:0045071 | ISG15                            | Ubiquitin-like protein ISG15    | Regulation of multi-organism process |
| GO:1903901 | EIF2AK2                          | Eukaryotic translation initiation factor 2-alpha kinase EIF2-alpha kinase-related | Regulation of multi-organism process |
|         | EIFIT1                            | Interferon-induced protein with tetratricopeptide repeat | Defense response to virus |
|         | OASL                              | 2.5 Oligoadenylate synthase     | Regulation of multi-organism process |
|         | RSAD2                             | Radical s-adenosyl methionine domain-containing protein 2 | N/A |
|         | ISG15                             | Ubiquitin-like protein ISG15    | Modification-dependent protein catabolic process |
|         | CXCL8                             | Cxc chemokine                   | Cellular response to lipopolysaccharide |

### Table 3

| Rank | Biological process | Adj. P-value | Genes involved |
|------|--------------------|--------------|----------------|
| 1    | Toll-like receptor signaling pathway | 0.025        | CXCL10, CXCL8, CCL3L1, IL1B, CCL3 |
| 2    | Cellular response to type I interferon | 3.93E-08     | IFITM1, RSAD2, IFI27, ISG15, HLA-A, IFIT1, IFIT2, OASL |
| 3    | Regulation of viral genome replication | 4.14E-07     | IFITM1, CXCL8, RSAD2, IFI2AK2, ISG15, HLA-A, IFIT1, IFIT3, IFIT2, OASL |
| 4    | Negative regulation of viral genome replication | 2.14E-06    | IFITM1, RSAD2, IFI2AK2, ISG15, IFIT1, APOBECA3A, OASL |
| 5    | Negative regulation of viral life cycle | 7.20E-06     | IFITM1, RSAD2, IFI2AK2, ISG15, IFIT1, APOBECA3A, OASL |
| 6    | Cytokine-mediated signaling pathway | 5.34E-05     | IFITM1, CXCL8, RSAD2, CCL3L1, ISG15, HLA-A, PPPB, IFIT1, IFIT3, OASL, IFIT2, CXCL10, IFI27, IL1B, CCL3 |
| 7    | Chemokine-mediated signaling pathway | 0.002        | CXCL10, CXCL8, CCL3L1, CCL3, PPPB |
| 8    | Inflammatory response | 0.008        | CXCL10, CXCL8, CCL3L1, NLRP7, IL1B, CCL3, PPPB, SIGLEC1 |
| 9    | Cellular response to lipopolysaccharide | 0.024        | CXCL10, CXCL8, NLRP7, IL1B, CCL3 |

### Table 4

| Gene                     | GO Biological Processes                                      |
|--------------------------|-------------------------------------------------------------|
| CXCL8                    | N/A                                                         |
| APOBECA3A                | mRNA editing enzyme                                         |
| RSAD2                    | Radical s-adenosyl methionine domain-containing protein 2 |
| ISG15                    | Ubiquitin-like protein ISG15                                 |
| GO:0045069               | Negative regulation of cellular process                     |
| GO:0045071               | RNA modification                                            |
| GO:1903901               | RNA-dependent DNA biosynthetic process                      |
Table 3
Gene ontology enrichment analysis using PANTHER overrepresentation test.

| Rank | Biological process | Adj. P-value | Genes involved |
|------|--------------------|--------------|----------------|
| 1    | Defense response to virus (GO:0051607) | 6.70E-11 | IFITM1, RSAD2, IFI27, ISG15, HERC5, IFIT1, IFIT2, OASL, CXCL10, APOBEC3A, EIF2AK2, IFIT3, IFI44L, NTS5CA |
| 2    | Response to virus (GO:0009615) | 3.19E-09 | IFITM1, RSAD2, IFI27, ISG15, HERC5, IFIT1, IFIT2, OASL, CXCL10, APOBEC3A, EIF2AK2, IFIT3, IFI44L, NTS5CA |
| 3    | Regulation of viral genome replication (GO:0045069) | 7.45E-08 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, RSAD2, CXCL8, IFITM1, IFI27 |
| 4    | Regulation of viral life cycle (GO:1903900) | 1.56E-06 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, RSAD2, CXCL8, IFITM1, IFI27 |
| 5    | Regulation of viral process (GO:0050792) | 1.59E-06 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, RSAD2, CXCL8, CCL3, IFI27, IFITM1 |
| 6    | Negative regulation of viral genome replication (GO:0045071) | 1.98E-06 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, RSAD2, CXCL8, CCL3, IFI27, IFITM1 |
| 7    | Negative regulation of viral process (GO:0048525) | 2.05E-06 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, RSAD2, IFITM1, CCL3 |
| 8    | Negative regulation of viral life cycle (GO:1903901) | 0.008 | EIF2AK2, ISG5, IFIT1, APOBEC3A, OASL, IFITM1, RSAD2 |

Table 4
PANTHER classification of viral biological processes enriched genes obtained from PANTHR overrepresentation test.

| GO ID     | Gene          | PANTHER family           | Biological Process                                                                 |
|-----------|---------------|--------------------------|-----------------------------------------------------------------------------------|
| GO:0051607| APOBC3A       | mRNA editing enzyme       | • Negative regulation of cellular process                                          |
| GO:0009615|               |                          | • RNA modification                                                                |
| GO:0045069|               |                          | • RNA-dependent DNA biosynthetic process                                          |
| GO:1903900|               |                          | • RNA phosphodiester bond hydrolysis, exonucleolytic                               |
| GO:0045071|               |                          | • Regulation of multi-organism process                                            |
| GO:0048525|               |                          | • Transposition                                                                   |
| GO:0050792|               |                          | • Defense response to virus                                                       |
|            | IFIT1         | Eukaryotic translation initiation factor 2- alpha kinase EIF2- alpha kinase-related |
|            | IFITM1        | Interferon-induced protein with tetracopeptide repeats | • Regulation of multi-organism process                                            |
|            |               | Interferon inducible transmembrane protein | • Negative regulation of biological process                                     |
|            |               |                          | • Type I interferon signaling pathway                                              |
|            |               |                          | • Defense response to virus                                                       |
| GO:0051607| ISG15         | 2-5 Oligoadenylate synthase | • Regulation of RNA metabolic process                                              |
| GO:0009615|               |                          | • Regulation of multi-organism process                                             |
| GO:0045069|               |                          | • Negative regulation of biological process                                       |
| GO:1903900|               |                          | • Regulation of hydrolyase activity                                               |
| GO:0050792|               |                          | • Defense response to virus                                                       |
| GO:0048525| RSAD2         | Radical s-adenosyl methionine domain-containing protein 2 | • RNA phosphodiester bond hydrolysis                                              |
| GO:0009615| ISG15         | Ubiquitin-like protein ISG15 | N/A                                                                               |
|            | IFI27         | Interferon alpha-inducible protein 27 | • Modification dependent protein catabolic process                                   |
|            | IFIT2         | Interferon-induced protein with tetracopeptide repeats | • Protein ubiquitination                                                         |
|            | IFIT3         | Interferon-induced protein with tetracopeptide repeats | • Aprotopic signaling pathway                                                    |
| GO:0051607| CXCL10        | Cxc chemokine           | • Granulocyte chemotaxis                                                          |
| GO:0009615|               |                          | • Cellular response to lipopolysaccharide                                          |
| GO:0045069|               |                          | • Antimicrobial humoral immune response mediated                                   |

processes good candidates for further investigation (Lin et al., 2016) (Figs. 1–3). We therefore report the fold change expression of these genes in addition to the rank of each common biological process in (Table 5).

Using STRING tool v11.0, we were able to obtain protein-protein interaction network through functional enrichment analysis for these mutually enriched genes, as depicted in Fig. 4 (Szklarczyk et al., 2019). Edges represent protein interactions while nodes represent proteins. Colored nodes represent first-degree interactions, while white nodes (not included in the figure) represent second-degree interactions. Empty nodes indicate that these proteins have unknown 3D structures. Each edge color indicates the type of interaction that can be known interactions, predicted interactions, and others.

6. Discussion and conclusion

BCG vaccine was shown to modulate the immune responses against tuberculosis and other microbial infection, and was shown to be effective against positive sense-RNA viruses. SARS-CoV2 is a positive sense RNA virus, against which monocytes represent the main cells of the immune response. This paper shows that BCG vaccination modulates the monocytes immune response to be more effective against SARS-CoV2. Our analysis showed differential expression of genes related to toll-like receptor (TLR) pathway in the monocytes of BCG vaccinated individuals, including upregulation of CXCL10 and downregulation of CXCL8, CCL3L1, IL1B, CCL3.

TLR pathway is important for viral infection. TLRs are composed of 10 family members, TLR1 to 10 (Karina et al., 2019), mainly present in macrophages, epithelial cells and fibroblasts (Karina et al., 2019). TLRs stimulation initiates the innate immune response, leading to the production of inflammatory mediators such as CXCL10, CXCL9, IL1B, CCL3 and interferon 1 (Karina et al., 2019). Single stranded RNA viruses interact with TLR7, making it the most likely to recognize SARS-COV-2 (Choi et al., 1993a). Stimulation of TLR7 induces the expression of CXCL8 and the secretion of IL-6 and TNFα (Davey et al., 2014).
Inhibition of TLR7, on the other hand, by BCG vaccination, may block the effector of TLR7 through inhibition of CXCL8 (Davey et al., 2014). IL1B is a pro-inflammatory cytokine that mediates the initiation of the monocyte immune response (Pulugulla et al., 2018) against RNA viruses such as influenza A virus and Sendai virus (Sareneva et al., 1998; Matikainen et al., 2000). Our data showed that monocytes from BCG vaccinated individuals downregulated IL1B expression. Our analysis showed also a decline in the levels of expression of CCL3L1 and CCL3 in monocytes isolated from BCG vaccinated individuals. In severe COVID-19 however, increased levels of CCL3L1 and CCL3 were reported (Arts et al., 2018a; Hernigou et al., 2015). Taken together, these data suggest that BCG vaccination may help in ameliorating the infectivity of SARS-CoV2.

The observed increase in CXCL10 expression is known to have a central role in immune-viral defenses and is correlated with the severity of virus-associated acute respiratory infections (Hayney et al., 2017). CXCL8 is found to be secreted by alveolar macrophages in acute inflammation and respiratory diseases in the lungs, this helps to initiate pro-inflammatory response and recruit other immune cells to the site of inflammation (Gauglitz et al., 2008; Harada et al., 1994). Despite the beneficial immunological response provided by the CXCL8 during inflammatory conditions, it can also contribute to the inflammatory complications and neutrophil-mediated tissue damage (Kaur and Singh, 2013; Moore and Kunkel, 2019). In addition, it was found that upregulated CXCL8 in patients with respiratory problems might correlate with their high risk to develop ARDS and may be associated with increased mortality rate (Chollet-Martin et al., 1993b; Miller et al., 1992; Pugin et al., 1999). Unlike CXCL10, according to our results, CXCL8 was downregulated in monocytes, which may reflect better outcomes to patients previously injected with BCG vaccine (Table 2).

The interferon-induced protein with tetratricopeptide repeats (IFIT) family is composed of 5 members, IFIT 1 through 5 (Brownlee, 1994). These IFITs are regulated by Interferon pathway since they have IFN-stimulated response elements promoters upon viral infection (Brownlee, 1994). These IFITs can detect and respond against viral infection by recognizing RNA with their 5' triphosphate and lacking 2'-O methylation, and sequesters these viral nucleic acids (Pichlmair et al., 2011). Elevated expression levels of IFIT1 upon BCG administration could therefore indicate enhanced

| GO ID      | Gene                  | PANTHER family          | Biological Process                                                                 |
|------------|-----------------------|-------------------------|------------------------------------------------------------------------------------|
| NT5C3A     | S'-nucleotidase       | Interferon-induced      | • Inflammatory response                                                            |
| IFI44L     | protein 44            | protein 44              | • Chemokine-mediated signaling pathway                                            |
| HERC5      | Ubiquitin-protein     | Ubiquitin-protein       | • Immune response                                                                  |
|            | ligase e3a-related    | ligase e3a-related      |                                                                                   |
| GO:0050792 | CCL3                  | Small inducible         | • ERK1 and ERK2 cascade                                                            |
|            |                       | cytokine A              | • Granulocyte chemotaxis                                                           |
|            |                       |                         | • G protein-coupled receptor signaling pathway                                      |
|            |                       |                         | • Cellular response to tumor necrosis factor                                        |
|            |                       |                         | • Innate immune response                                                           |
|            |                       |                         | • Lymphocyte migration                                                              |
|            |                       |                         | • Positive regulation of GTPase activity                                            |
|            |                       |                         | • Response to interleukin-1                                                        |
|            |                       |                         | • Inflammatory response                                                            |
|            |                       |                         | • Chemokine-mediated signaling pathway                                            |
|            |                       |                         | • Cellular response to lipopolysaccharide                                          |
|            |                       |                         | • Granulocyte chemotaxis                                                           |
|            |                       |                         | • Chemokine-mediated signaling pathway                                            |
|            |                       |                         | • Antimicrobial humoral immune response mediated by antimicrobial peptide          |
|            |                       |                         | • Immune response                                                                  |
|            |                       |                         | • Inflammatory response                                                            |
|            |                       |                         | • Regulation of molecular function                                                 |

Inhibition of TLR7, on the other hand, by BCG vaccination, may block the effector of TLR7 through inhibition of CXCL8 (Davey et al., 2014). IL1B is a pro-inflammatory cytokine that mediates the initiation of the monocyte immune response (Pulugulla et al., 2018) against RNA viruses such as influenza A virus and Sendai virus (Sareneva et al., 1998; Matikainen et al., 2000). Our data showed that monocytes from BCG vaccinated individuals downregulated IL1B expression. Our analysis showed also a decline in the levels of expression of CCL3L1 and CCL3 in monocytes isolated from BCG vaccinated individuals. In severe COVID-19 however, increased levels of CCL3L1 and CCL3 were reported (Arts et al., 2018a; Hernigou et al., 2015). Taken together, these data suggest that BCG vaccination may help in ameliorating the infectivity of SARS-CoV2.

The observed increase in CXCL10 expression is known to have a central role in immune-viral defenses and is correlated with the severity of virus-associated acute respiratory infections (Hayney et al., 2017). CXCL8 is found to be secreted by alveolar macrophages in acute inflammation and respiratory diseases in the lungs, this helps to initiate pro-inflammatory response and recruit other immune cells to the site of inflammation (Gauglitz et al., 2008; Harada et al., 1994). Despite the beneficial immunological response provided by the CXCL8 during inflammatory conditions, it can also contribute to the inflammatory complications and neutrophil-mediated tissue damage (Kaur and Singh, 2013; Moore and Kunkel, 2019). In addition, it was found that upregulated CXCL8 in patients with respiratory problems might correlate with their high risk to develop ARDS and may be associated with increased mortality rate (Chollet-Martin et al., 1993b; Miller et al., 1992; Pugin et al., 1999). Unlike CXCL10, according to our results, CXCL8 was downregulated in monocytes, which may reflect better outcomes to patients previously injected with BCG vaccine (Table 2).

The interferon-induced protein with tetratricopeptide repeats (IFIT) family is composed of 5 members, IFIT 1 through 5 (Brownlee, 1994). These IFITs are regulated by Interferon pathway since they have IFN-stimulated response elements promoters upon viral infection (Brownlee, 1994). These IFITs can detect and respond against viral infection by recognizing RNA with their 5' triphosphate and lacking 2'-O methylation, and sequesters these viral nucleic acids (Pichlmair et al., 2011). Elevated expression levels of IFIT1 upon BCG administration could therefore indicate enhanced
cellular innate immunity against SARS-CoV-2 infection. Different kinds of viruses can evade the action of IFIT1 by having a 2′-O-MTase activity including coronaviruses, as reviewed by Diamond et al. (Diamond, 2014). Thus, targeting viral 2′-O-MTases has been of great interest. For example, therapeutics that target SARS-CoV-2 nsp16 2′-O-MTase have been investigated as potential novel SARS-CoV-2 inhibitors (Yuanyuan et al., 2020). Administration of BCG vaccine along with viral-specific drugs and therapeutics may result in boosted results.

Type 1 interferon pathway is one of the main pathways to be stimulated by viral infection, that is triggered by pathogen-associated molecular patterns (PAMPs) (Fan and Sun, 2016). PAMPs induce the upregulation of Interferon-stimulated gene (ISGs) (Elkhenany et al., 2019; Hayflick, 1975). ISGs stimulation causes inhibition of viral replication in addition to recruitment of immune cells and enhanced tissue repair (Van Tienen et al., 2011; Cianfarani et al., 2013). In SARS-COV-2 infection, there is a delayed and ineffective type 1 interferon response (George and Abrahamse, 2019; Yoon et al., 2011).

Table 5

| Mutually enriched biological processes | Rank in PANTHER | Rank in Enrichr |
|----------------------------------------|-----------------|-----------------|
| Regulation of viral genome replication (GO:0045069) | 3 | 3 |
| Negative regulation of viral life cycle (GO:1903901) | 4 | 5 |
| Negative regulation of viral genome replication (GO:0045071) | 6 | 4 |

| Mutually enriched genes | Log (FC) |
|-------------------------|----------|
| IFIT1                   | 2.119    |
| CXCL8                   | -2.268   |
| ISG15                   | 1.367    |
| EIF2AK2                 | 0.84     |
| OASL                    | 1.419    |
| IFITM1                  | 2.278    |
| RSAD2                   | 2.001    |

Fig. 3. Nest Venn diagram for the commonly enriched genes and biological processes from PANTHER overrepresentation test and Enrichr analysis.

Fig. 4. Protein-protein interaction network of commonly enriched genes, generated by STRING v11.0.

Kozlowska et al., 2019; Han et al., 2014). In serum of patients with SARS-COV-2, there is a decrease in type 1 interferon (Randeria et al., 2019; Cawthorn and Sethi, 2008). This exacerbates the cytokine storm via recruitment of monocytes and macrophages (George and Abrahamse, 2019; Yoon et al., 2011). ISG15 has also been shown to exhibit broad spectrum of antiviral activities through different mechanisms, as reviewed in (Morales and Lenschow, 2013; Harty et al., 2009). It was shown to be upregulated upon administration of BCG vaccine, which further confirms that BCG administration enhances antiviral properties. SARS-CoV2, however, has been shown to alleviate some of ISG15 antiviral activities through the action of papain-like protease which de-SGylate viral proteins (Niemeyer et al., 2018; Lindner et al., 2007). This
can be justified by other antiviral activities that ISG15 exerts other than ISGylation of viral proteins. This also can be further supported by the fact that ISG15 can delay coronaviruses replication (Ma et al., 2014). In SARS-CoV2, papain-like protease inhibition enhanced antiviral immunity to SARS-CoV2 (Shin et al., 2020). This indicates that BCG administration along with other therapeutics can substantially foster immunity against SARS-CoV2 infection.

Among the interferon stimulated genes are the IFITM family, which is considered the first line of antiviral defense, and includes IFITM1, as reviewed by Smith et al. (Bailey et al., 2014). IFITM1 protein has been shown to exert antiviral activities among different types of viruses including SARS coronaviruses (Smith et al., 2019; Huang et al., 2011). IFITM1 has been shown to be upregulated upon SARS-CoV2 infection where log2FC = 0.6736, 1.0275 (Lzogathan et al., 2020; Blanco-Melo, 2020). Comparing the previous results to our analyzed dataset shows that BCG vaccination can induce more expression of IFITM1 (Log2FC = -2.276) and therefore enhances antiviral immunity and response to SARS-CoV2.

RSAD2, also known as viper in, has been shown to have antiviral activity against several types of viruses via different interferon-dependent and independent pathways, as reviewed by Seo et al. (2011). One of the mechanisms by which RSAD2 acts as an antiviral protein is via the generation of 3′-(2011). One of the mechanisms by which RSAD2 acts as an antiviral protein is via the generation of 3′-deoxy-3′,4′-didehydro-CTP (ddhCTP) which acts as a chain terminator for RNA-dependent RNA polymerases (Gizzi et al., 2018). Viperin has been shown to interact with Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1) and inhibits its expression (Vonderer et al., 2018). GBF1 depletion was previously shown to result in reduced SARS-CoV2 infection (de Wilde et al., 2015). Accordingly, higher expression of viperin can be a potential candidate for ameliorating SARS-CoV2 infection. The higher expression of viperin upon BCG administration could also boost host cells immune defense against SARS-CoV2 infection.

OASL is an interferon-induced protein with antiviral activities that include activation of RIG-1 and RNase I (Zhu et al., 2014; Choi et al., 2015). OASL was found to be upregulated in SARS-CoV2 infected cells (Daneshe et al., 2011). It was also found to be upregulated after administration of BCG vaccine. This could support the innate cellular antiviral activities in SARS-CoV2 infections. EIF2AK2 is another interferon-induced dsRNA-activated protein that has antiviral activities. EIF2AK2 expression was upregulated upon BCG administration. For its spectrum of antiviral activity, EIF2AK2 gene is suspected to be one of the genes stimulated by BCG vaccine to boost the antiviral cellular innate immunity.

As can be inferred, most of the common enriched genes are interferon-inducible genes that have antiviral mechanisms except for the CXCL8 chemokine. All these genes, except CXCL8, were upregulated as per the performed data analysis upon BCG vaccine administration. This indicates that BCG can foster innate cellular antiviral responses against the novel SARS-CoV2 viral infection. Although SARS-CoV2 has evasion mechanisms against some of these upregulated antiviral factors, BCG administration along with other drugs can overcome such evasion mechanism.

Our data have also shown no significance in the expression of ACE2 in monocytes isolated from BCG vaccinated individuals. ACE2 receptor, which is responsible for infectivity of cells with SARS-CoV2, this suggests that monocyte infection with SARS-CoV2 may still possible in these individuals. Taken together, our data support the premise that trained immunity developed in patients previously vaccinated with BCG can induce a cross-protection mechanism against SARS-CoV2 (Kleinnijenhuis et al., 2015; Covian et al., 2019) Vaccinated BCG patients may thus experience enhanced immune responses against SARS-CoV2 especially in old aged patient segment, albeit not ensuring decreased infectivity of SARS-CoV2. Clinical trials using BCG vaccine to enhance immunity against SARS-CoV2 are essential to confirm these findings.

CRediT authorship contribution statement

Sara M. Ahmed: Methodology, Investigation, Writing – original draft, Writing – review & editing. Mohamed A. Nasr: Software, Formal analysis, Writing – original draft. Shima E. Elshenawy: Writing – original draft. Alaa E. Hussein: Writing – original draft. Ahmed H. El-Betar: Conceptualization, Writing – original draft. Rania Hassan Mohamed: Writing – review & editing. Nagwa El-Badri: Writing – review & editing, Supervision.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements and Funding:

This work was supported by grant number #5300 from the Science and Technology Development Fund (STDF), and by internal funding from Zewail City of Science and Technology.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.virol.2021.10.003.

References

Aaby, P., et al., 1984. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J. Infect. 8 (1), 13–21.
Aaby, P., et al., 2011. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? JID (J. Infect. Dis.) 204 (2), 245–252.
Acotta, J.C., et al., 2013. A complex secretory program orchestrated by the novel SARS-CoV2 viral infection. Although SARS-CoV2 has evasion activities in SARS-CoV2 infections. EIF2AK2 is another interferon-induced dsRNA-activated protein that has antiviral activities. Bioinformatics 25 (22), 3045–3046.
Arndolusen, D.L., Linehan, M., Sheikh, A., 2011. BCG vaccination and allergy: a systematic review and meta-analysis. J. Allergy Clin. Immunol. 127 (1), 246–253 e21.
Arts, R.J., et al., 2018a. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23 (1), 89–100 e5.
Arts, R.J.W., et al., 2018b. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23 (1), 89–100 e5.
Asbell, M., et al., 2000. Gene ontology: tool for the unification of biology. Gene Ontol. Consort. Nat. Gene. 25 (1), 25–29.
Bailey, C.C., et al., 2014. IFITM-family proteins: the cell and animal defense against SARS-CoV2 infection.
Bailey, C.C., et al., 2014. IFITM-family proteins: the cell and animal defense against SARS-CoV2 infection.
Bhansali, A., et al., 2009. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell. Dev. 18 (10), 1407–1416.
Binn, D., et al., 2009. QuickGO: a web-based tool for Gene Ontology searching. Bioinformatics 25 (22), 3045–3046.
Blanco-Melo, D., et al., 2020. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. bioRxiv 181, 1036–1416.
Brandl, A., et al., 2011. Oxidative stress induces senescence in human mesenchymal stem cells. Exp. Cell Res. 317 (11), 1541–1547.
Brownlee, M., 1994. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 154, 2473–2479.
Campisi, J., Di Fagagna, F.D.A., 2007. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8 (9), 729–740.
Carbon, S., et al., 2008. AmiGO: online access to ontology and annotation data. Bioinformatics 25 (2), 288–289.
Cawthorn, W.P., Sethi, J.K., 2008. TNF-α and adipocyte biology. FEBS Lett. 581, 739–740.
Chang, T.-C., Hsu, M.-F., Wu, K.K., 2015. High glucose induces bone marrow-derived mesenchymal stem cell senescence in human through the induction of cytokines associated with trained immunity. Cell Host Microbe 23 (1), 89–100 e5.
Choi, U.Y., et al., 2015. Oligoadenylate synthase-like (OASL) proteins: dual functions and technology development fund (STDF), and by internal funding from Zewail City of Science and Technology.
Chollet-Martín, S., et al., 1993b. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect. Immun. 61 (11), 4555–4561.
Choo, K.-H., et al., 2014. Oxidative stress-induced premature senescence in Wharton’s jelly-derived mesenchymal stem cells. Int. J. Med. Sci. 11 (11), 1201.
Cianfarani, F., et al., 2013. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Biomed. Res. Ther. 6 (3), 3073–3081.
Davey, G.C., et al., 2014. Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus. Front. Endocrinol. 5, 86.
de Lima, K.A., et al., 2016. Transcriptional profiling reveals intrinsic mRNA alterations in multipotent mesenchymal stromal cells isolated from bone marrow of newly-diagnosed type 1 diabetes patients. Stem Cell Res. Ther. 7 (1), 1–16.
de Wilde, A.J.H., et al., 2015. A kinome-wide small interfering RNA screen identifies proviral and antiviral host factors in severe acute respiratory syndrome coronavirus replication, including double-stranded RNA-activated protein kinase e and early pathwayway proteins. J. Virol. 89 (16), 8318.
Diamond, M.S., 2014. IFIT1: a dual sensor and effector molecule that detects non-2′-O-methylated viral RNA and inhibits its translation. Cytokine Growth Factor Rev. 25 (4), 433–456.
El-Badawy, A., El-Badry, N., Dhar, M., 2019. Green propolis extract promotes in vitro proliferation, differentiation, and migration of bone marrow stromal cells. Biomed. Pharmacother. 115, 108861.
Faghihian, M., et al., 2015. Percutaneous injection of bone marrow mesenchymal stem cells into the myocutaneous defect improves wound healing and accelerates epidermal regeneration. Wound Repair Regen. 23 (6), 564–573.
Gauglitz, G.G., et al., 2008. Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive? Crit. Care (3), 12 p.
Girzi, A.S., et al., 2018. Naturally occurring antiviral ribonuclease encoded by the human genome. Nature 558 (7711), 610–614.
Gorsel, M. and I. Gursel, 2015. Global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Medical Hypotheses, 2020.
Ha, S.M., et al., 2016. Enhanced proliferation and differentiation of Oct4-and Sox2-overexpressing human adipose tissue mesenchymal stem cells. Exp. Mol. Med. (6), 46 p. e101.e1.
Ha, H., et al., 2013. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem. Biophys. Res. Commun. 436 (3), 418–423.
Harada, A., et al., 1994. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J. Leukoc. Biol. 56 (5), 559–564.
Harry, R.M., Pitta, P.M., Okamura, A., 2009. Antiviral activity of innate immune protein ISG15. J. Innate Immun. 1 (5), 397–404.
Hayflick, L., 1975. Cell biology of aging. Bioscience 25 (10), 629–637.
Hayney, M.S., et al., 2017. Serum IFN-γ/alpha-induced protein 10 (IFI10) as a biomarker for severity of acute respiratory infection in healthy adults. J. Clin. Virol. 90, 32–37.
Hernigou, P., et al., 2015. Percutaneous injection of bone marrow mesenchymal stem cells into the myocutaneous defect improves wound healing and accelerates epidermal regeneration. Wound Repair Regen. 23 (6), 564–573.
Helmchen, H., et al., 2016. Impact of the source and serial passaging of goat bone marrow-derived mesenchymal stromal cells. Sci. Transl. Med. 8 (352), 1–15.
Helmchen, H., El-Badry, N., Dhar, M., 2019. Green propolis extract promotes in vitro proliferation, differentiation, and migration of bone marrow stromal cells. Biomed. Pharmacother. 115, 108861.
Hershberg, R.M., et al., 2013. IFIT1 is an antiviral protein that recognizes 5′-triphosphate–O-methylated viral RNA and inhibits its translation. Cytokine Growth Factor Rev. 25 (24), 499–5008.
Hicks, I.K., et al., 2018. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. (D1), 47 p. D419–D426.
Miller, E.J., et al., 1992. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis. 146 (2), 427–432.
Moore, B.B., Kunkel, S.L., 2019. Attracting attention: discovery of IL-6/CXCL8 and the birth of the chemokine field. J. Immunol. 202 (1), 3.
Moonag, S., et al., 2019. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25 (12), 1473–1482.
Moraes, D.J., Lenschow, D.J., 2019. The antiviral activities of ISG15. J. Mol. Biol. 425 (24), 4959–5008.
Mourits, V.P., et al., 2020. The role of Toll-like receptor 10 in modulation of trained immunity. Immunology 159 (3), 289–297.
Netes, M.G., Quintin, J., Van Der Meer, J.W., 2011. Trained immunity: a memory for innate host defense. Cell Host Microbe 9 (5), 355–361.
Niemeier, D., et al., 2018. The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species. PLoS Pathog. (9), 14 p. e1007296.
Orajio, A.V., et al., 2009. Cell surface-bound IL-1α is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. Unit. States Am. 106 (40), 17031–17036.
Osemlin, C., Kucuksezer, U.C., Tamay, Z.U., 2020. BCG vaccination affecting the spread and severity of COVID-19? Allergy 75 (7), 1824–1827.
Panina, Y.A., et al., 2019. Plasticity of adipose tissue-derived stem cells and regulation of angiogenesis. Front. Physiol. 9, 1656.
Patella, V., et al., 2020. Could anti-tubercular vaccination protect against COVID-19 infection? Allergy 75 (4), 942–945.
Patel, R.P., et al., 2021. An antiviral protein that recognizes 5′-triphosphate–O-methylated RNA. Nat. Immunol. 12 (7), 624–630.
Pugin, J., et al., 1999. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit. Care Med. 27 (2), 304–310.
Pul pulpulla, S.H., et al., 2018. Distinct mechanisms regulate IL18 gene transcription in lymphoid CD4 T cells and monocytes. Cytokine 111, 373–381.
Randeria, S.N., et al., 2019. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc. Diabetol. 18 (1), 1–15.
Reaven, G.M., 1988. Role of insulin resistance in human disease. Diabetes 37 (12), 1595–1607.
Rocha, C.R.R., et al., 2013. The role of DNA repair in the pluri potency and differentiation of human stem cells. Mutat. Res. Rev. Mutat. Res. 752 (1), 25–35.
Sánchez-Ramón, S., et al., 2018. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front. Immunol. 9, 6036.
Sareneva, T., et al., 1998. Influenza A virus-induced IFN-α gene expression and transcription factor activation in human macrophages. Virology 260 (1), 276–288.
Seo, E., et al., 2017. Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing. J. Transl. Med. 15 (1), 1.
Seo, J.-Y., Yaneva, R., Cresswell, P., 2011. Viperin: a multifunctional, interferon-γ-inducible protein that restricts viral replication. Cell Host Microbe 10 (1), 534–539.
Seo, E., et al., 2017. Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing. Tran. Med. 15 (1), 1–9.
Shin, J.H., Shin, D.W., Hoh, M., 2009. Interleukin-17A inhibits adipo cyte differentiation in human chondrogenic stem cell and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 77 (12), 1835–1844.
Shafaghi, A.H., Rokhsar Talabazar, F., Knør, A., Ghorbani, M., 2020. On the effect of the respiratory droplet generation condition on COVID-19 transmission. Fluids 5 (3), 3939.
Shin, D., et al., 2020. Inhibition of papain-like protease PI3po blocks SARS-CoV-2 spread and promotes anti-viral immunity. Research square.
Smith, R.J., Reid, A.L., 2018. The potential of adipose-derived stem cell subpopulations as regenerative medicine. Future medicine.
Smith, S.E., et al., Interferon-Induced Transmembrane Protein 1 Restricts Replication of Viruses That Enter Cells via the Plasma Membrane. Journal of Virology, 2019. 93(6): p. e00003-18.

Soto, J.A., et al., 2018. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity. Front. Immunol. 9, 2875.

Spencer, J.C., Ganguly, R., Waldman, R.H., 1977. Non-specific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. JID (J. Infect. Dis.) 136 (2), 171-175.

Stensballe, L.G., et al., 2005. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls: community based case-control study. Vaccine 23 (10), 1251–1257.

Szklarczyk, D., et al., 2019. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. (D1), 47 p. D607-d613.

Thacker, J., Zdzienicka, M.Z., 2003. The mammalian XRCC genes: their roles in DNA repair and genetic stability. DNA Repair 2 (6), 655-672.

Thacker, J., Zdzienicka, M.Z., 2004. The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair 3 (8-9), 1081–1090.

The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. (D1), 2019, 47 p. D330-d338.

Van Tienen, F., et al., 2011. Preadipocytes of type 2 diabetes subjects display an intrinsic gene expression profile of decreased differentiation capacity. Int. J. Obes. 35 (9), 1154-1164.

Vercruysse, S., Venkatesan, A., Kuiper, M., 2012. OLSVis: an animated, interactive visual browser for bio-ontologies. BMC Bioinf. 13, 116.

Volpe, C.M.O., et al., 2018. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 9 (2), 1–9.

Vonderstein, K., et al., 2018. Viperin targets flavivirus virulence by inducing assembly of noninfectious capsid particles. J. Virol. (1), 92 p. e01751-17.

Wang, D., et al., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 323 (11), 1061–1069.

Yao, D., Brownlee, M., 2010. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59 (1), 249–255.

Yuanyuan, J., et al., 2020. Repurposing Therapeutics to Identify Novel Inhibitors Targeting 2'-O-Ribose Methyltransferase Nsp16 of SARS-CoV-2.

Zhang, H., et al., 2012. Adipose tissue-derived stem cells ameliorate diabetic bladder dysfunction in a type II diabetic rat model. Stem Cell. Dev. 21 (9), 1391–1400.

Zhang, D., et al., 2020. COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J. Leukoc. Biol. 109, 13–22.

Zhou, F., Tu, Y., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, R., Gu, X., Guan, L., 2020 Mar. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 28395 (10229), 1054–1062.

Zhu, J., et al., 2014. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 40 (6), 936–948.

Zhu, L., et al., 2020. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabol. 31, 1068–1077.

Zimmermann, P., Curtis, N., 2018. The influence of BCG on vaccine responses - a systematic review. Expert Rev. Vaccines 17 (6), 547-554.

Tung NT, Cheng PC, Chi KH, Hsiao TC, Jones T, BéruBé K, Ho KP, Chuang HC. Particulate matter and SARS-CoV-2: a possible model of COVID-19 transmission. Science of The Total Environment. 2021 Jan 1,750:141532.